AMARILLO - Local businesspeople can learn from experts in artificial intelligence, branding, marketing and more during the WT ...
At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) ...
Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of ...
Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...